U.S. markets closed
  • S&P Futures

    3,877.50
    +10.00 (+0.26%)
     
  • Dow Futures

    31,437.00
    +79.00 (+0.25%)
     
  • Nasdaq Futures

    13,107.50
    +52.25 (+0.40%)
     
  • Russell 2000 Futures

    2,242.50
    +13.40 (+0.60%)
     
  • Crude Oil

    59.88
    +0.13 (+0.22%)
     
  • Gold

    1,731.30
    -2.30 (-0.13%)
     
  • Silver

    26.76
    -0.12 (-0.44%)
     
  • EUR/USD

    1.2089
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • Vix

    24.10
    +0.75 (+3.21%)
     
  • GBP/USD

    1.3957
    +0.0000 (+0.00%)
     
  • USD/JPY

    106.8300
    +0.1200 (+0.11%)
     
  • BTC-USD

    48,738.83
    -322.13 (-0.66%)
     
  • CMC Crypto 200

    976.49
    -10.16 (-1.03%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,450.20
    +42.03 (+0.14%)
     

Inventiva’s 2020 Full-Year Financial Results Presentation

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
INVENTIVA
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.


Daix (France), February 23, 2021
– Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will host a webcast to present the Company’s full-year financial results for 2020 on Friday, March 5, 2021.

Inventiva’s 2020 full-year financial results will be released on Thursday, March 4, 2021 at 4:00 pm (New York), 10:00 pm (Paris).

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, on Friday, March 5, 2021 at 8:00 am (New York), 2:00 pm (Paris).

The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/wr8srgzq and also available on Inventiva’s onwards in the “Investors” – “Financial results” section.


To join the conference call, please use the code 3586531 after dialing one of the following numbers:

France: +33 (0) 1 70 70 07 81
Belgium: +32 (0) 2 793 3847
Germany: +49 (0) 69 2222 2625
Netherlands: +31 (0) 20 795 6614
Switzerland: +41 (0) 44 580 7145
United Kingdom: +44 (0) 207 192 8338
United States: +1 646-741-3167


Please note that the line will be opened 10 minutes before the start of the conference call.

A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com


Contacts

Inventiva
Frédéric Cren
Chairman & CEO
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick Group
Yannick Tetzlaff /
Tristan Roquet Montegon /
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank

Investor relations
patti.bank@westwicke.com
+1 415 513-1284

Attachment